(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 January 2009 (15.01.2009)

PCT

(10) International Publication Number
WO 2009/009470 A1

(51) International Patent Classification:
A61K 9/19 (2006.01) *A61K 31/433* (2006.01)

(21) International Application Number:
PCT/US2008/069301

(22) International Filing Date: 7 July 2008 (07.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/949,268 12 July 2007 (12.07.2007) US

(71) Applicants *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **KYOWA HAKKO KOGYO CO., LTD.** [JP/JP]; 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KUSANO, Hiroko** [JP/JP]; Kyowa Hakko Kogyo Co., Ltd., 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP). **MISHRA, Dinesh, Shyamdeo** [US/US]; 2504 Sutton Avene, Carmel, Indiana 46032 (US). **TASHIRO, Yoshikazu** [JP/JP]; Kyowa Hakko Kogyo Co., Ltd., 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP). **WATANABE, Yosuke** [JP/JP]; Kyowa Hakko Kogyo Co., Ltd., 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP). **ZHUANG, Hong** [CN/US]; 3887 Branch Creek Court, Zionsville, Indiana, Indianapolis, Indiana 46077 (US).

(74) Agents: **HOSTETTLER, Danica** et al.; Eli Lilly and Company, Patent Division, P.O. Box 6288, Indianapolis, Indiana 46285 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report*

(54) Title: STABLE FORMULATIONS OF THIADIAZOLE DERIVATIIVE

(57) Abstract: The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimeth yl-propionamide that minimize undesirable chiral conversion to the less active S enantiomeric form.

WO 2009/009470 A1